Dermata Therapeutics Warrant
DRMAW
4 hedge funds and large institutions have $13.7K invested in Dermata Therapeutics Warrant in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 0 closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
0.48% less ownership
Funds ownership: 2.61% → 2.13% (-0.48%)
34% less capital invested
Capital invested by funds: $20.9K → $13.7K (-$7.18K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$136 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
1
Boothbay Fund Management
New York
| $12.7K | – | – | – |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $525 | – | – | – |
|
|
AC
3
Armistice Capital
New York
| $355 | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $101 | +$136 | +5,610 | New |
|
DRMAW Hedge Fund Activity: Q3 2023 in Review
4 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q3 2023, worth a combined $13.7K — down 34% from $20.9K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new DRMAW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $136.
- 4 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q3 2023, up from 3 in Q2 2023.
- Funds reported $13.7K of Dermata Therapeutics Warrant stock for Q3 2023, down 34% quarter-over-quarter.
- 1 fund opened new Dermata Therapeutics Warrant positions in Q3 2023 and 0 closed out, a net change of +1 holder.
- The largest Dermata Therapeutics Warrant buyer in Q3 2023 was UBS Group, an estimated $136 added.
Based on aggregated 13F filings for Q3 2023.